Pharma De-prioritization Intelligence

The shelved-asset-scout is a specialized pharmaceutical intelligence skill designed for investors, M&A analysts, and licensing professionals. In the fast-moving biotech landscape, pharmaceutical giants often quietly "shelf" promising assets due to strategic pivots, restructuring, or resource reallocation. This skill surfaces those hidden opportunities by analyzing years of corporate communications.

What it does

This tool utilizes a sophisticated multi-phase workflow to detect assets that have been deprioritized or discontinued. It connects to the PharmaceuticIndex MCP server to access a deep corpus of press releases and corporate data. It doesn't just look for explicit keywords like "discontinued"; it uses a Long-Arc Method to identify "communication cliffs"—where an asset mentioned regularly suddenly vanishes from the corporate narrative while overall company activity remains stable.

Key Features

• Signal Taxonomy: Categorizes opportunities into five distinct rungs, including EOL corporate-speak, strategy pivots, and out-licensing solicitations.
• Gap vs. Silence Discrimination: Employs logic to distinguish between actual asset deprioritization and systemic data ingestion artifacts.
• Semantic Confirmation: Leverages Voyage embeddings to confirm asset absence and detect if a company has pivoted focus to a different therapeutic area.
• Cadence Calibration: Automatically assesses if a company publishes frequently enough for "silence" to be a statistically significant investment signal.

Why use this skill?

Monitoring thousands of pipeline assets manually is impossible. Standard keyword searches often fail because companies use nuanced "corporate-speak" to bury bad news or strategic shifts. This skill automates the detection of multi-year silence arcs, providing a structured, confidence-weighted list of candidates ready for acquisition or licensing outreach.